Geranylgeranyl diphosphate synthase: an emerging therapeutic target
- PMID: 22048229
- DOI: 10.1038/clpt.2011.215
Geranylgeranyl diphosphate synthase: an emerging therapeutic target
Abstract
Proteins modified post-translationally by geranylgeranylation have been implicated in numerous cellular processes related to human disease. In recent years, the study of protein geranylgeranylation has advanced tremendously in both cellular and animal models. The advances in our understanding of the biological roles of geranylgeranylated proteins have been paralleled by advances in the medicinal chemistry of geranylgeranylation inhibitors such as those that target geranylgeranyl transferases I and II and geranylgeranyl diphosphate synthase (GGDPS). Although these findings provide the rationale for further development of geranylgeranylation as a therapeutic target, more advanced studies on the efficacy of this approach in various disease models will be required to support translation to clinical studies. This article attempts to describe the advances in (and the challenges of) validation of GGDPS as a novel therapeutic target and assesses the advantages of targeting GGDPS relative to other enzymes involved in geranylgeranylation.
Similar articles
-
Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.Molecules. 2017 May 27;22(6):886. doi: 10.3390/molecules22060886. Molecules. 2017. PMID: 28555000 Free PMC article. Review.
-
Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.Bioorg Med Chem. 2008 Jan 1;16(1):390-9. doi: 10.1016/j.bmc.2007.09.029. Epub 2007 Sep 18. Bioorg Med Chem. 2008. PMID: 17905588
-
Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins.J Med Chem. 1996 Mar 29;39(7):1352-6. doi: 10.1021/jm960127s. J Med Chem. 1996. PMID: 8691464
-
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. doi: 10.1006/abbi.1999.1502. Arch Biochem Biophys. 2000. PMID: 10620343
-
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.Oncogene. 2000 Dec 27;19(56):6584-93. doi: 10.1038/sj.onc.1204146. Oncogene. 2000. PMID: 11426643 Review.
Cited by
-
Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.Mol Membr Biol. 2016 Mar;33(1-2):1-11. doi: 10.1080/09687688.2016.1213432. Epub 2016 Aug 18. Mol Membr Biol. 2016. PMID: 27537059 Free PMC article. Review.
-
Stereoselective Synthesis of Homoneryl and Homogeranyl Triazole Bisphosphonates.J Org Chem. 2016 Oct 7;81(19):9438-9442. doi: 10.1021/acs.joc.6b01693. Epub 2016 Sep 20. J Org Chem. 2016. PMID: 27648672 Free PMC article.
-
S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8.Nature. 2019 Mar;567(7747):244-248. doi: 10.1038/s41586-019-1003-z. Epub 2019 Mar 6. Nature. 2019. PMID: 30842656 Free PMC article.
-
Synthetic Routes to Methylerythritol Phosphate Pathway Intermediates and Downstream Isoprenoids.Curr Org Chem. 2014 Apr;18(8):1050-1072. doi: 10.2174/1385272819666140501001101. Curr Org Chem. 2014. PMID: 25009443 Free PMC article.
-
Boosting synergism of chemo- and immuno-therapies via switching paclitaxel-induced apoptosis to mevalonate metabolism-triggered ferroptosis by bisphosphonate coordination lipid nanogranules.Acta Pharm Sin B. 2024 Feb;14(2):836-853. doi: 10.1016/j.apsb.2023.08.029. Epub 2023 Sep 4. Acta Pharm Sin B. 2024. PMID: 38322346 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
